Oxidative stress and the endothelium

Experimental Physiology

Volumn 93, Issue 1, 2008, Pages 155-157

  Wadsworth, R M ^a  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; ANTICOAGULANT AGENT; MATRIGEL; NITRIC OXIDE; PLASMINOGEN ACTIVATOR; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE;

CARDIOVASCULAR RISK; CONFERENCE PAPER; ENDOTHELIUM; ENDOTHELIUM CELL; ENDOTHELIUM LESION; FIBROBLAST; HUMAN; INSULIN RESISTANCE; MEDIATOR; METABOLIC DISORDER; OXIDATIVE STRESS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; VASCULAR DISEASE;

EID: 37349127318     PISSN: 09580670     EISSN: 1469445X     Source Type: Journal    
DOI: 10.1113/expphysiol.2007.038687     Document Type: Conference Paper

References (20)

1. Cifuentes ME & Pagano PJ (2006). Targeting reactive oxygen species in hypertension. Curr Opin Nephrol Hypertens 15, 179 186.
2. Cifuentes ME, Rey FE, Carretero OA & Pagano PJ (2000). Upregulation of p67 (phox) and gp91 (phox) in aortas from angiotensin II-infused mice. Am J Physiol Heart Circ Physiol 279, H2234 H2240.
3. Di Wang H, Pagano PJY, Cayatte AJ, Quinn MT, Brecher P & Cohen RA (1998). Superoxide anion from the adventitia of the rat thoracic aorta inactivates nitric oxide. Circ Res 82, 810 818.
4. Furuki K, Adachi H, Matsuoka H, Enomoto M, Satoh A, Hino A, Hirai Y & Imaizumi T (2007). Plasma levels of asymmetric dimethylarginine (ADMA) are related to intima-media thickness of the carotid artery: an epidemiological study. Atherosclerosis 191, 206 210.
5. Kearney MT, Duncan ER, Kahn M & Wheatcroft SB (2007). Insulin resistance and endothelial cell dysfunction: studies in mammalian models. Exp Physiol 93, 000 000.
6. Leiper J, Nandi M, Torondel B, Murray-Rust J, Malaki M, O'Hara B, Rossiter S, Anthony S, Madhani M, Selwood D, Smith C, Wojciak-Stothard B, Rudiger A, Stidwill R, McDonald NQ & Vallance P (2007). Disruption of methylarginine metabolism impairs vascular homeostasis. Nat Med 13, 198 203.
7. Leiper JM & Vallance P (2006). The synthesis and metabolism of asymmetric dimethylarginine (ADMA). Eur J Clin Pharmacol 62 (Suppl. 1 33 38.
8. Mills NL, Tornqvist H, Robinson SD, Gonzalez M, Darnley K, MacNee W, Boon NA, Donaldson K, Blomberg A, Sandstrom T & Newby DE (2005). Diesel exhaust inhalation causes vascular dysfunction and impaired endogenous fibrinolysis. Circulation 112, 3930 3936.
9. Oliver JJ, Webb DJ & Newby DE (2005). Stimulated tissue plasminogen activator release as a marker of endothelial function in humans. Arterioscler Thromb Vasc Biol 25, 2470 2479.
10. Pagano PJ, Chanock SJ, Siwik DA, Colucci WS & Clark JK (1998). Angiotensin II induces p67 (phox) mRNA expression and NADPH oxidase superoxide generation in rabbit aortic adventitial fibroblasts. Hypertension 32, 331 337.
11. Pagano PJ, Clark JK, Cifuentes-Pagano ME, Clark SM, Callis GM & Quinn MT (1997). Localization of a constitutively active, phagocyte-like NADPH oxidase in rabbit aortic adventitia: enhancement by angiotensin II. Proc Natl Acad Sci U S A 94, 14483 14488.
12. Pagano PJ, Ito Y, Tornheim K, Gallop PM, Tauber AI & Cohen RA (1995). An NADPH oxidase superoxide-generating system in the rabbit aorta. Am J Physiol Heart Circ Physiol 268, H2274 H2280.
13. Rey FE, Li XC, Carretero OA, Garvin JL & Pagano PJ (2002). Perivascular superoxide anion contributes to impairment of endothelium-dependent relaxation role of gp91(phox). Circulation 106, 2497 2502.
14. Rey FE & Pagano PJ (2002). The reactive adventitia: fibroblast oxidase in vascular function. Arterioscler Thromb Vasc Biol 22, 1962 1971.
15. Robinson SD, Harding SA, Cummins P, Din JN, Sarma J, Davidson I, Fox KAA, Boon NA & Newby DE (2006a). Functional interplay between platelet activation and endothelial dysfunction in patients with coronary heart disease. Platelets 17, 158 162.
16. Robinson SD, Ludlam CA, Boon NA & Newby DE (2006b). Tissue plasminogen activator genetic polymorphisms do not influence tissue plasminogen activator release in patients with coronary heart disease. J Thromb Haemost 4, 2262 2269.
17. Rossiter S, Smith CL, Malaki M, Nandi M, Gill H, Leiper JM, Vallance P & Selwood DL (2005). Selective substrate-based inhibitors of mammalian dimethylarginine dimethylaminohydrolase. J Med Chem 48, 4670 4678.
18. Smith CL, Birdsey GM, Anthony S, Arrigoni FI, Leiper JM & Vallance P (2003). Dimethylarginine dimethylaminohydrolase activity modulates ADMA levels, VEGF expression, and cell phenotype. Biochem Biophys Res Commun 308, 984 989.
19. Touyz RM, Yao G, Quinn MT, Pagano PJ & Schiffrin EL (2005). p47phox associates with the cytoskeleton through cortactin in human vascular smooth muscle cells: role in NAD(P)H oxidase regulation by angiotensin II. Arterioscler Thromb Vasc Biol 25, 512 518.
20. Weaver M, Liu JH, Pimentel D, Reddy DJ, Harding P, Peterson EL & Pagano PJ (2006). Adventitial delivery of dominant-negative p67 (phox) attenuates neointimal hyperplasia of the rat carotid artery. Am J Physiol Heart Circ Physiol 290, H1933 H1941.